Suzuki et al. [19] investigated the clinicopathological features of 46 patients with CD4+ and/or CD56+ immature hematolymphoid malignancy (iHLM), including blastic plasmacytoid dendritic cell neoplasm (BPDCN). This evidence concerns the gene CD4 and CD4+/CD56+ hematodermic neoplasm.